Loading...

NBY NOVABAY PHARMACEUTICALS INC Contract Awards 8-K Filing

NVBY

NBY

NOVABAY PHARMACEUTICALS INC

(NBY)

2025 8-K

Stock Preferences Update

Compliance Regained

Major Stock Changes

CEO Resignation

Special Dividend Announcement

Special Cash Dividend

Investment Agreement

Company Liquidation

Settlement Agreements

Advisory Agreement

Asset Sale Update

CEO Contract Extension

Special Meeting Update

Special Meeting Results

Asset Sale Update

Asset Sale Update

Asset Sale Announcement

Asset Sale Agreement

Public Offering

Earnings Report

Warrant Reprice Transactions

Reverse Stock Split

Sale of Subsidiary

Delisting Notice

Update Presentation

Delisting Notice

Completion of Asset Sale

Entry into a Material Defin...

License Agreement with Sono...

Warrant Reprice Transactions

Management Extension

Amendment to Bylaws and Ann...

Private Placement

Private Placement

Resignation and Appointment

External Links:

On October 9, 2025, David Lazar resigned as CEO of NovaBay Pharmaceuticals, Inc. in connection with a Securities Purchase Agreement transferring approximately 90% of shares to new investors, pending stockholder approval at the upcoming meeting on October 16, 2025.

AI Assistant

NOVABAY PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.